TCF21  genetic polymorphisms and breast cancer risk in Chinese women

Xueren Gao; Jiaojiao Yang; Mingxi Wang; Jianqiong Zhang

doi:10.18632/oncotarget.9825

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

TCF21 genetic polymorphisms and breast cancer risk in Chinese women

Xueren Gao, Jiaojiao Yang, Mingxi Wang and Jianqiong Zhang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:55757-55764. https://doi.org/10.18632/oncotarget.9825

Metrics: PDF 1956 views | HTML 2850 views | ?

Abstract

Xueren Gao1,2, Jiaojiao Yang1,2, Mingxi Wang3 and Jianqiong Zhang1,2

1 Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China

2 Jiangsu Key Laboratory of Molecule Imaging and Functional Imaging, Medical School of Southeast University, Nanjing, Jiangsu, China

3 Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

Correspondence to:

Jianqiong Zhang, email:

Keywords: polymorphism, breast cancer, risk

Received: March 07, 2016 Accepted: May 20, 2016 Published: June 05, 2016

Abstract

Transcription factor 21 (TCF21) functions as a tumor suppressor and is inactivated in several types of cancer. The purpose of this study is to investigate whether TCF21 genetic polymorphisms(rs2327429 T>C, rs2327430 T>C, rs2327433 A>G, rs12190287 C>G, rs7766238 G>A, rs4896011 T>A) are associated with the risk of breast cancer in Chinese women. Logistic regression analyses showed that TCF21 rs12190287 polymorphism was significantly associated with the reduced risk of breast cancer. Stratified analyses based on pathological type indicated that TCF21 rs12190287 polymorphism was only associated with the reduced risk of infiltrative ductal carcinoma. Real-time quantitative PCR analyses revealed that compared with those carrying rs12190287 CC genotype, subjects with GG genotype had higher expression levels of TCF21 mRNA in normal breast tissues. Furthermore, luciferase activity assay showed that the rs12190287 G allele weakened the binding affinity of hsa-miR-224 to TCF21 3’ UTR. These findings suggest that TCF21 rs12190287 polymorphism can regulate TCF21 expression and may serve as a potential marker for genetic susceptibility to breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9825

Publication Alerts

Post-Publication Promotion

Publication Discount

Clinical Research Papers:

TCF21 genetic polymorphisms and breast cancer risk in Chinese women

Abstract